Congress should work to rescind the 2.3% excise tax on medical devices in the health care law because it will stifle innovation and job growth, Boston Scientific President and CEO Ray Elliott writes in this Star Tribune opinion. Repealing the tax "would help protect the 2 million Americans whose jobs are supported by the medical technology sector and remove burdens on a uniquely American industry that collectively spends more than $10 billion annually on R&D, boasts a net trade surplus and has historically led the world in developing leading-edge medical technologies," Elliott writes.

Related Summaries